

---

# RIBAPHARM Patents

Matching "RIBAPHARM" by Owner.

**IPMonitor**  
Patents

---

# Contents

Alerts	3
"RIBAPHARM"	3
Terms and Conditions	4
General	4
Disclaimer of warranty and limitation of liability	4
Copyright	4
Arbitration	4

# Alerts

## "RIBAPHARM"

19 results matching "RIBAPHARM" by Owner.

Number	Title	Owner
<a href="#">2002312487</a>	NUCLEOSIDE VACCINE ADJUVANTS	RIBAPHARM
<a href="#">2002323350</a>	NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS	RIBAPHARM INC.
<a href="#">2002327168</a>	PYRROLO(2,3-D)PYRIMIDINE NUCLEOSIDE ANALOGS	RIBAPHARM INC.
<a href="#">2002334788</a>	TRICYCLIC NUCLEOSIDE LIBRARY COMPOUNDS, SYNTHESIS, AND USE AS ANTIVIRAL AGENTS	RIBAPHARM INC.
<a href="#">2002340387</a>	CYTIDINE LIBRARIES AND COMPOUNDS SYNTHESIZED BY SOLIDPHASE COMBINATORIAL STRATEGIES	RIBAPHARM INC.
<a href="#">2002341942</a>	SUGAR MODIFIED NUCLEOSIDES AS VIRAL REPLICATION INHIBITORS	RIBAPHARM INC.
<a href="#">2002348042</a>	2'-BETA-MODIFIED-6-SUBSTITUTED ADENOSINE ANALOGS AND THEIR USE AS ANTIVIRAL AGENTS	RIBAPHARM INC.
<a href="#">2002348162</a>	ANTIVIRAL COMBINATION THERAPY AND COMPOSITIONS	RIBAPHARM INC.
<a href="#">2002349905</a>	NUCLEOSIDE LIBRARIES AND COMPOUNDS BY MCC COMBINATORIAL STRATEGIES ON SOLID SUPPORT	RIBAPHARM INC.
<a href="#">2002353164</a>	UNUSUAL NUCLEOSIDE LIBRARIES, COMPOUNDS, AND PREFERRED USES AS ANTIVIRAL AND ANTICANCER AGENTS	RIBAPHARM INC.
<a href="#">2002353165</a>	DEAZAPURINE NUCLEOSIDE LIBRARIES AND COMPOUNDS	RIBAPHARM INC.
<a href="#">2002357876</a>	NUCLEOSIDE ANALOG LIBRARIES AND COMPOUNDS	RIBAPHARM INC.
<a href="#">2002357925</a>	PARALLEL INDUCIBLE CELL-BASED KINASE SCREEN	RIBAPHARM INC.
<a href="#">2002359732</a>	SUBSTITUTED PURINE NUCLEOSIDE LIBRARIES AND COMPOUNDS BY SOLID-PHASE COMBINATORIAL STRATEGIES	RIBAPHARM INC.
<a href="#">2003207605</a>	DEAZAPURINE NUCLEOSIDE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS	RIBAPHARM INC.
<a href="#">2003209285</a>	DEAZAPURINE NUCLEOSIDE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS	RIBAPHARM INC.
<a href="#">2003225705</a>	CYTIDINE ANALOGS AND METHODS OF USE	RIBAPHARM INC.
<a href="#">2002368154</a>	IMPROVED SYNTHESIS FOR HYDROXYALKYLATED HETEROCYCLIC BASES	RIBAPHARM INC.
<a href="#">2001273670</a>	Pyrido(2,3-d)pyrimidine and pyrimido(4,5-d)pyrimidine nucleosides	Ribapharm Inc.

---

# Terms and Conditions

## General

The information provided in this report is not in the nature of legal or other professional advice.

The information provided in this report is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals regarding any information in this report.

Patents, patent applications, trademarks and trademark applications shown as lapsed or ceased may be restored at a later date.

## Disclaimer of warranty and limitation of liability

Neither IPMonitor, its affiliates nor any of their respective employees, agents, third party content providers or licensors warrant that the information contained in this report is error free; nor do they make any warranty as to the accuracy, reliability or content of any information in this report.

This report is provided on an "as is" basis; to the maximum extent permitted by law, IPMonitor disclaims all representations and warranties, express or implied, with respect to any information contained in this report. In addition, IPMonitor does not represent or warrant that the information contained in this report is accurate, complete or current.

This disclaimer of liability applies to any damages or injury caused by any failure of performance, error, omission, interruption, deletion, defect, delay in operation or transmission, computer virus, communication line failure, theft or destruction or unauthorized access to, alteration of, or use of record, whether for breach of contract, tortious behavior, negligence, or under any other cause of action.

## Copyright

The content of this report may be protected by copyright laws and treaties around the world and all rights relating to the same are reserved. Any paper or digital copies of this report are not to be modified or any illustrations or any graphics used separately from any accompanying text.

## Arbitration

Any dispute or difference whatsoever arising out of or in connection with this report shall be submitted to arbitration in accordance with, and subject to, The Institute of Arbitrators & Mediators Australia Rules for the Conduct of Commercial Arbitrations.

IPMonitor reserves the right to update the Terms and Conditions at any time without notice. Please see the full Terms and Conditions at [www.IPMonitor.com.au/trademarks/info/terms](http://www.IPMonitor.com.au/trademarks/info/terms)